The aim of our study was to examine changes in levels of vascular growth factors in pregnant women with chronic hypertension (CH). There was carried out a clinical analysis of pregnancy, childbirth, postpartum and postnatal outcomes in 69 pregnant women with CH and 49 women with physiological course of pregnancy. The levels of proangiogenic (PlGF) and antiangiogenic (sFlt-1, sEng) factors in the serum of 28–34 weeks' gestation were investigated in all pregnant women with immune-enzyme analysis. At pregnancy with the CH there was observed an increase in the concentration of antiangiogenic proteins sFlt-1 to 5573 ± 774 pg/ml (3299 ± 544 pg/ml in control, p < 0.05) and endoglin to 7.1 ± 0.8 ng/ml (control 5.4 ± 0.4 ng/ml, p < 0.05). At the same time there was a decrease of proangiogenic PlGF (155.8 ± 30.4 pg/ml vs 238.5 ± 66.1 pg/ml in controls, p < 0.05).